Skip to main content
US EQUITIES AFTER-HOURS CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
AD

ADXNStockAddex Therapeutics Ltd - ADR

SWISS EXCHANGE · Healthcare · CH

$3.06 last close 2026-11-18
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment ADXN's does — no target price to set, unlike a price alert.

Sharia status
COMPLIANT
Per our secondary compliance provider · assessed 2026-08-06
0 of 1 pass our own screen — 6 of 7 could not be computed
HTR non-permissible income <0.01%

Methodology breakdown computing — it will appear here on its own.

🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
⚪ NEUTRAL — No Edge
Signals are mixed with no clear edge in either direction. Stand aside and wait for one more confluence factor.
Scores: 2 bullish / 2 bearish
31
of 100
Setup confidence — system conviction, not win probabilityF

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure0 of 4 timeframes bullish · 41.2% aligned
VWAPPrice below VWAP ($5.16)
VolumeRelative volume 19.7× the 20-day average
Momentum10-day rate of change +1.8%
Overall readNEUTRAL — No Edge

Addex Therapeutics Ltd - ADR (ADXN) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-06). See the full ratio breakdown and business-activity screen below for the reasoning.

This sits among 434 compliant Healthcare stocks we track. See compliant Healthcare stocks →

Market & analysts
Wall Street consensus
SELL
9 analysts
Institutional own.
0.0%
of shares
Momentum (10d)
+1.8%
rate of change
SMC grade
F · 31
41.2% aligned
<0.01%
Non-permissible income — HTR, from filings (2025-06-30)
F · 31
SMC grade — 41.2% timeframe alignment
+1.8%
Rate of change (10d)
SELL
Wall Street consensus (9)
0.0%
Institutional ownership

🕌 In-house Compliance Research

Computing the full ratio and business-activity breakdown for ADXN — this runs off the critical path so the page paints first. It will appear here on its own.

Shariah-compliant alternatives

Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
VRTXVertex Pharmaceuticals, Inc. $121.1B —
REGNRegeneron Pharmaceuticals, Inc. $85.3B —
ARGXArgen X SE - ADR $64.3B —
ONCBeOne Medicines Ltd. American Depositary Shares $40.4B —
ALNYAlnylam Pharmaceuticals Inc $31.6B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Tracked investors holding ADXN
InvestorFirmPositionWeightAs of
Ken Griffin Citadel Advisors $0M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

8.997.405.824.242.652025-11-192026-05-212026-11-18

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
3.07
S2
3.29
S1
3.39
PIVOT
3.61
R1
3.71
R2
3.93
R3
4.03

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
2.97 – 4.33
±18.54% from 3.65, made 2026-09-27 · resolves 2026-10-04
SELL
from 19 indicators
77.1% of our last 20463 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 50.1% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
19 indicators
OscillatorsSTRONG BUY
5 buy · 2 neutral · 0 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 12 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)47.30NEUTRAL
Stochastic %K (14)9.95BUY
CCI (20)-2.42NEUTRAL
Williams %R (14)-90.05BUY
MACD (12,26,9)0.06BUY
ROC (10)0.56BUY
Momentum (10)0.02BUY
EMA (10)3.45SELL
SMA (10)3.41SELL
EMA (20)3.32SELL
SMA (20)3.19SELL
EMA (30)3.30SELL
SMA (30)3.12SELL
EMA (50)3.46SELL
SMA (50)3.18SELL
EMA (100)4.12SELL
SMA (100)4.23SELL
EMA (200)5.31SELL
SMA (200)5.50SELL

About Addex Therapeutics Ltd - ADR

Healthcare · Biotechnology

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

addextherapeutics.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Verdict

⚪ NEUTRAL — No Edge

Signals are mixed with no clear edge in either direction. Stand aside and wait for one more confluence factor.

Scores: 2 bullish / 2 bearish

Grade verdict

No real edge — avoid

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily RANGING 42
🕐 1H BEARISH 54
⏱ 15-Min BEARISH 130
⏲ 5-Min BEARISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

+1.8%
Rate of change (10d)
19.7×
Volume vs its 20-day average
0.14
MACD (no fresh cross)
$3.53
Volume POC (today)
$3.17 – $3.60
Value area

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-10 · Asset managers net 914130 (-14454)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.